Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse. Authors' Reply
- PMID: 40321062
- DOI: 10.1111/apt.70180
Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse. Authors' Reply
References
-
- C. Frimor and M. A. Ainsworth, “Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse,” Alimentary Pharmacology & Therapeutics 61, no. 12 (2025): 1965–1966.
-
- Y. Takagi, T. Sato, T. Nishiguchi, et al., “Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study,” Alimentary Pharmacology & Therapeutics 61, no. 12 (2025): 1923–1934, https://doi.org/10.1111/apt.70140.
-
- J. St‐Pierre, D. Choi, E. Fear, et al., “Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real‐World Data in a Population From a Large Tertiary Center,” Digestive Diseases and Sciences (2025): 1–9.
-
- T. Sawada, M. Nakamura, T. Yamamura, et al., “Efficacy of Mirikizumab in Patients With Prior Ustekinumab Exposure: A Case Series,” Inflammatory Bowel Diseases (2025): izaf018.
-
- G. D'Haens, M. Dubinsky, T. Kobayashi, et al., “Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis,” New England Journal of Medicine 388, no. 26 (2023): 2444–2455.
Publication types
LinkOut - more resources
Full Text Sources